Humanigen, Inc. ('Humanigen') announced it entered into an agreement with PCI Pharma Services (PCI), to provide importation, release and commercialization services in the United Kingdom (UK) for lenzilumab. Under the agreement, PCI will purchase lenzilumab for resale and distribution in the event a Conditional Marketing Authorization is received in the UK for use in patients hospitalized with COVID-19.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | -66.67% | -50.00% | -91.67% |
12/04 | Combined Liquidation Plan and Disclosure Statement Filed by Humanigen, Inc. | CI |
08/03 | Final DIP Financing Approved for Humanigen, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
-91.67% | 11.91T | |
-2.91% | 8.9TCr | |
-4.34% | 3.78TCr | |
-17.11% | 3.12TCr | |
+60.58% | 2.61TCr | |
-22.56% | 1.43TCr | |
-9.36% | 1.28TCr | |
-11.39% | 1.16TCr | |
+3.82% | 870.27Cr | |
-17.54% | 745.49Cr |
- Stock Market
- Equities
- HGEN.Q Stock
- News Humanigen, Inc.
- Humanigen Enters into Agreement with PCI Pharma Services as Part of Preparations for Commercialization in the United Kingdom